Why Is CLOVER HEALTH INVTS A (CLOV) Stock Up Today?

CLOV stock surged 21.06% to $5.02 in Monday trading, driven by a combination of strong earnings results and an upward revision to full-year revenue guidance. The company reported GAAP earnings per share of $0.05, exceeding estimates by $0.02, and revenue of $743.17 million, which beat expectations by $14.9 million. Clover also raised its FY 2026 revenue guidance to a range of $2.92 billion to $3.0 billion, reflecting confidence in its AI-driven Medicare Advantage growth strategy.

What Happened

Clover Health released its Q2 2026 earnings results on August 5, with the stock opening at $4.55, a 9.9% gap up from the previous close. The company’s earnings call highlighted its 4.5-Star rating, which provides flexibility for 2027, and outlined continued momentum in its MA business. The SEC 8-K filing confirmed the results and guidance update, while the slide deck and transcript from the earnings call provided further details on operational performance. The stock’s sharp intraday rally pushed it to a session high of $5.19, with the last trade at $4.99.

What The Data Shows

The stock’s 52-week range is $1.58 to $5.59, and the current price is near the upper end of that range. Year-to-date revenue has grown by 48.7%, but the company remains unprofitable with a TTM net margin of -2.6%. The session’s volume of 1.0 million shares is 0.1x the 3-month daily average, suggesting limited retail or institutional participation. Over the last 8 sessions, the stock had fallen 3.0% from $4.27 to $4.14 before Monday’s reversal. Insider transactions in the last 90 days totaled 18 sales worth $4.1 million, with the most recent on July 20.

What To Watch

The stock is currently priced at $4.99, and investors should monitor the company’s ability to maintain its guidance and improve profitability. No earnings date is scheduled in the near term, but coverage breadth and any follow-up commentary from analysts will be key to the stock’s near-term direction.